The EC granted Marketing Authorisation for Vueway® (gadopiclenol) in the European Union Vueway®, a new macrocyclic gadolinium-based contrast agent for CE-MRI, received Marketing Authorisation in the European Union By European Commission.

Samsung Medison and Bracco Imaging announce a new agreement Samsung Medison and Bracco Imaging endorsed a Memorandum of Understanding agreement to pioneer a new area for diagnostic ultrasound device and contrast agent at European Congress of Radiology 2024 held in Vienna, Austria on February 28th to March 3rd.

The Bracco Group announces the newly-created Bracco Japan The Bracco Group announces its direct presence in the Japanese market, where it has been doing business since 1990 through a successful joint venture with Eisai

Bracco Suisse and Verasonics: a new strategic partnership The collaboration focuses on combining Verasonics' Vantage®️ NXT Research Ultrasound Systems with Bracco's contrast agents to explore improved imaging performance in various research applications.

Blue Earth Diagnostics appoints Marco Campione as Chief Executive Officer Mr. Campione brings more than 25 years global experience in successful development and commercialization of diagnostic imaging agents and radiopharmaceuticals.

Bracco Imaging and Arrayus Technologies: a new strategic partnership Bracco Imaging and Arrayus Technologies have partnered to improve drug delivery for pancreatic cancer using focused ultrasound and microbubble technology.

AI Pills in Medical Writing This webinar series, in collaboration with Springer Healthcare Italia, a global leader in healthcare education and communication, is designed to provide radiologists with practical insights into the use of innovative digital tools and technologies to improve the effectiveness of medical writing.

Gadopiclenol receives the JFR 2024 Innovation Award Bracco Imaging is delighted to announce that Gadopiclenol (marketed as Vueway® by Bracco) has been honored with the JFR 2024 Innovation Award in the Jury's Favorite category.

Bracco Diagnostics and Subtle Medical Announce FDA Clearance of AiMIFY™ Software Bracco Diagnostics Inc. and Subtle Medical, Inc. are thrilled to announce that their collaborative AI-powered software, AiMIFYTM, has received FDA clearance as a Class II software as a medical device (SaMD) for magnetic resonance imaging (MRI) of the brain.

Bracco triples production of its innovative ultrasound contrast agent in Geneva Over 80 million euros has been invested to build Hexagon, a new manufacturing facility located next to the historical 1996 plant which will, when fully operational, triple the production and distribution of one of the leading products from Bracco's research.